liposyn iii 30% Drug Patent Profile
✉ Email this page to a colleague
When do Liposyn Iii 30% patents expire, and what generic alternatives are available?
Liposyn Iii 30% is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in LIPOSYN III 30% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
Summary for liposyn iii 30%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 4 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for liposyn iii 30% |
DailyMed Link: | liposyn iii 30% at DailyMed |
Recent Clinical Trials for liposyn iii 30%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Cleveland Clinic | Early Phase 1 |
Pennington Biomedical Research Center | Early Phase 1 |
The University of Texas Health Science Center at San Antonio | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for liposyn iii 30%
US Patents and Regulatory Information for liposyn iii 30%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | LIPOSYN III 30% | soybean oil | INJECTABLE;INJECTION | 020181-001 | Jan 13, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for liposyn iii 30%
When does loss-of-exclusivity occur for liposyn iii 30%?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 0632
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 13247058
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2014025232
Estimated Expiration: ⤷ Try a Trial
China
Patent: 4220113
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 36259
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 36259
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 01769
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 28339
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 4450
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 73462
Estimated Expiration: ⤷ Try a Trial
Patent: 15516201
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 1343
Estimated Expiration: ⤷ Try a Trial
Patent: 14012226
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 36259
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 30597
Estimated Expiration: ⤷ Try a Trial
Patent: 14144631
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 2124661
Estimated Expiration: ⤷ Try a Trial
Patent: 150003199
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 88510
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 68466
Estimated Expiration: ⤷ Try a Trial
Patent: 1402163
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering liposyn iii 30% around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Argentina | 090632 | PORTADOR DE CARTUCHO E INYECTOR DEL TIPO DE BOLIGRAFO | ⤷ Try a Trial |
Hungary | E028339 | ⤷ Try a Trial | |
Poland | 2836259 | ⤷ Try a Trial | |
Japan | 2015516201 | カートリッジホルダおよびペン型注射器 | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |